Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-Arterial Magnesium Therapy After Mechanical Thrombectomy in Acute Ischemic Stroke
NCT06956521Phase 1Recruiting
- Sponsor
- Baylor College of Medicine
- Start
- Jul 2026
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of magnesium sulfate in ischemic stroke (4 arms), sponsored by Baylor College of Medicine. Primary endpoints: Systemic Magnesium Sulfate Concentration at 24 hours and Proportion of severe adverse events at 48 hours. Started Jul 2026; status: recruiting.
02
Drugs
magnesium sulfate
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06956521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06956521.